• 全球疫情的逐渐缓解使得经济复苏成为各国政府的首要任务。
  • 随着人口老龄化的加剧,养老服务和健康管理需求日益增长。
  • 气候变化引发的极端天气事件频发,全球减排行动迫在眉睫。
  • 智能家居设备的发展正在引领家庭生活向更智能、更环保的方向发展。
  • 网络安全威胁的增加迫使企业和个人加强数据保护措施。
  • 电子商务的快速发展对传统零售业造成了巨大冲击。
  • 随着全球疫苗接种率的提高,经济复苏的希望逐渐增强。
  • 全球健康危机促使各国加强公共卫生体系的建设和改革。
  • 生物多样性的保护成为全球环境保护的核心议题。
  • 在线教育的兴起为教育资源的公平分配提供了新途径。
  • 随着太空探索的进展,商业航天领域迎来了新的发展机遇。
  • 全球经济正在逐步适应后疫情时代的新常态。
  • 电子商务的增长推动了物流行业的创新和发展。
  • 随着人口老龄化,养老服务和健康管理成为社会关注的新焦点。
  • 生物多样性的丧失成为全球生态保护的紧迫问题。
  • 移动支付和数字货币的普及正在改变人们的支付习惯。
  • 医疗保健行业的数字化转型为疾病预防和治疗带来新机遇。
  • 大数据在商业决策中的作用越来越重要。
  • 随着太空探索的进展,商业航天领域迎来了新的发展机遇。
  • 全球健康危机凸显了公共卫生体系的重要性和改革的必要性。
  • 电子竞技的流行正在改变传统体育和娱乐行业的格局。
  • 虚拟现实技术在游戏、教育和医疗领域的应用日益增多。
  • 智能家居设备的发展正在引领家庭生活向更智能、更环保的方向发展。
  • 大数据在商业分析和市场预测中发挥着关键作用。
  • 自动化和机器人技术在制造业中的应用提高了生产效率。
  • Optimal induction treatment regimens for extranodal NK/T-cell lymphoma: lessons learned, challenges, and proposals | Yang | Aging Pathobiology and Therapeutics
    Demo

    Open Access | Letter to Editor
    This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

    Optimal induction treatment regimens for extranodal NK/T-cell lymphoma: lessons learned, challenges, and proposals


    Jing Yanga, Ruiying Fua, Xindi Liua, Liqiang Weia, Liang Wanga,b*

    a Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
    b Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beihang University & Capital Medical University, Beijing Tongren Hospital, Beijing 100730, China.

    * Corresponding author: Liang Wang
    Mailing address: Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
    E-mail: wangliangtrhos@126.com

    Received: 23 November 2020 / Accepted: 16 December 2020

    DOI: 10.31491/APT.2020.12.045

    Extranodal NK/T-cell lymphoma (ENKTCL) is a highly aggressive and Epstein-Bar virus (EBV)-associated hematologic malignancy, most prevalent in the Far East and South America [1]. No standard treatment strategy has been defined. It is well recognized that combination of asparaginase-based chemotherapy (CT) and radiotherapy (RT) benefit early-stage ENKTCL. It has been validated that upfront RT can cure most stage I patients of ENKTCL without risk factors, and asparaginase (either L-asparaginase or pegaspargase) is the backbone of chemotherapy for ENKTCL. In recent years, a variety of asparaginasebased regimens have been found to be effective in earlystage ENKTCL, such as GELOX (gemcitabine, oxaliplatin, and asparaginase) [2] or EPOCHL (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and asparaginase) [3], but with different toxicities. Thus, we are wondering how much is too much for early-stage ENKTCL patients, and is intensive chemotherapy really necessary? Moreover, the international T-cell Project reported the updated survival outcomes of a large cohort of worldwide patients with ENKTCL (except Chinese) this year, and more than 60 regimens were used in this report, indicating a lack of standard treatment regimens [4]. Compared with the survival data of Chinese patients with ENKTCL, the outcomes reported by this international multi-center cohort seem unsatisfactory. Due to very small number of patients enrolled from the USA and no patients from China, it is of importance to show the data from these two large countries, which enable us to depict the real-world data of ENKTCL globally. In this multi-center Aging Pathobiology and Therapeutics 2020; 2(4):226-229 226 DOI: 10.31491/APT.2020.12.045 retrospective study, we compared the efficacy, long-term survival outcomes, and safety profiles between GELOX and EPOCHL regimen in early-stage ENKTCL patients. Meanwhile, the survival outcomes of all-stage patients from China and SEER (Surveillance, Epidemiology, and End Results) database were compared.
    A total of 494 patients of ENKTCL with all stages (AnnArbor stage I, n = 224; stage II, n = 168; stage III-IV, n = 102) from Beijing Tongren Hospital were included in this study, and all patients received asparaginasebased treatment, among whom 193 patients with stage I-II ENKTCL were treated with 4-6 cycles of GELOX (pegaspargase 2,500 IU/m2 d1, gemcitabine 1,000 mg/m2 d1, 8, oxaliplatin 100 mg/m2 d1, repeated every 3 weeks) or EPOCHL (etoposide 50 mg/m2 /d, vincristine 0.5 mg/d, doxorubicin 10 mg/m2 /d were administered by continuous intravenous infusion over 96 h d1-4, prednisone 60 mg/ m2 /d was administered orally on days 1-5, cyclophosphamide 750 mg/m2 was given as an intravenous bolus on day 5, L-asparaginase 10,000 U/d was administered by intravenous infusion on days 6-10 or pegaspargase 2500 IU/m2 d1, repeated every 3 weeks) regimen combined with radiotherapy (≥50Gy), either sequential or sandwich chemoradiation. Response to treatment was evaluated using MRI scan or PET-CT scan after chemotherapy and end of treatment. Progression free survival (PFS) was calculated from diagnosis of ENKTCL to disease progression, death of any reason, or last follow-up, whichever came first. Overall survival (OS) was defined from diagnosis to death of any reason, or last follow-up, whichever came first. The institutional ethics review board approved this study and all patients provided informed consent for publication of clinical data at their first visit, but all patients in this study had been de-identified. Moreover, we identified 1140 patients with ENKTCL from the SEER database (www.seer.cancer.gov) based on the ICD-O-3 code for histology (9719, ENKTCL) from 1987 to 2015, and 330 patients were excluded from our analysis due to unknown stage or missing detailed survival data.
    68 patients with early stage ENKTCL received GELOX induction therapy and 125 patients were treated with EPOCHL regimen. No significant difference was found between those two groups concerning baseline characteristics. At the end of treatment, a complete response (CR) rate of 75% and an overall response rate (ORR) of 98.5% was achieved in the GELOX group, and the CR rate and ORR were 56% and 94.4% in the EPOCHL group, respectively. Although there was no significant difference in ORR between GELOX and EPOCHL regimen, as is shown in Figure 1, patients treated with GELOX had significantly better PFS and OS than those with EPOCHL (p<0.05). Meanwhile, the safety profile of GELOX regimen was more favorable than EPOCHL, especially the hematology toxicities. As expected, patients with stage II disease had significantly inferior outcomes than those with stage I disease (p < 0.05). The end of treatment efficacy had a significant impact on the long-term survival outcomes, as patients with CR enjoyed more favorable PFS and OS than those without CR (p<0.05). In the GELOX cohort, efficacy assessment data was available before RT consolidation. As is shown in Figure 1-H, patients without CR after induction chemotherapy had significantly inferior PFS than those with CR (p = 0.033), though part of those patients could be salvaged by RT consolidation and attained CR at the end of RT.


    Figure 1. Survival curves for ENKTCL patients with localized disease. Patients treated with GELOX regimen had significantly better OS (A) and PFS (B) than those treated with EPOCHL. Patients with stage II disease h a d s i g n i f i c a n t l y inferior OS (C) and PFS (D) than those with stage I. The end of treatment response significantly correlated w i t h p r o g n o s i s o f ENKTCL (E, F). For patients treated with GELOX, CR before radiotherapy indicated significantly better PFS (H) and a trend for better OS (G). CR means complete response, RT means radiotherapy.

    The detailed baseline characteristics of both Chinese and SEER cohorts were shown in Table 1. More patients in the SEER database were treated before 2010 when asparaginase-based therapies were not well recognized. Moreover, significantly more patients in the SEER database had extra-nasal or non-upper aerodigestive tract (UADT) disease. The treatment strategies were unknown for the SEER database, and asparaginase-based chemotherapy with or without combined radiotherapy was administrated in the Chinese cohort. As is shown in Figure 2, the fiveyear OS rate was 79.4%, 56.6%, and 43.6% for patients with stage I, II, and III-IV, respectively, in the Chinese cohort, which seemed much better than that in the SEER database (55.2%, 35.6%, and 21.2%, respectively). This discrepancy may be caused by unbalanced baseline characteristics and different treatment strategies. Also, the etiology and biology of ENKTCL may differ between Asian and Western countries.


    Figure 2. Survival curves for patients of ENKTCL in the Chinese (A) and SEER (B) cohorts. AASS means Ann-Arbor staging system.

    Table1
    The baseline characteristics of ENKTCL patients.

    Chinese cohort
    (N= 494)
    SEER database
    (N=241)
    P value
    Year of diagnosis
    1987-2009
    2010-now
    191 (38.7%)
    303 (61.3%)
    443 (54.7%)
    367 (45.3%)
    P<0.001
    Gender
    Male
    Female
    335 (67.8%)
    159 (32.2%)
    524 (64.7%)
    286 (35.3%)
    P=0.274
    Age
    <60
    ≥60
    403
    91 (18.4%)
    513 (63.3%)
    297 (36.7%)
    P<0.001
    Ann-Arbor stage
    I
    II
    III-IV
    179 (36.2%)
    197 (39.9%)
    118 (23.9%)
    381 (47.0%)
    179 (22.1%)
    250 (30.9%)
    P<0.001
    Primary lymphoma site
    UADT
    Non-UADT
    Nasal cavity
    Extra-nasal sites
    452 (91.5%)
    42 (8.5%)
    320 (64.8%)
    174 (35.2%)
    596 (73.6%)
    214 (26.4%)
    387 (47.8%)
    423 (52.2%)
    P<0.001

    Due to the distinct geographic pattern of ENKTCL, many studies were done in Asian countries, and asparaginasebased induction therapies were well recognized, should be given in the first-line setting. Nowadays, risk-model guided therapy should be implemented in clinical practice [5]. For those localized diseases at low-risk, radiotherapy alone could achieve satisfactory results, and asparaginasebased chemotherapy should be added to radiotherapy for those with risk factors. The standard induction regimens were not defined yet, and our previous study demonstrated that pegaspargase monotherapy in combination with concurrent radiotherapy could attain 100% CR rate for early stage disease [6], which needs to be validated in phase 3 RCTs. Although the prognosis is much better for the Chinese cohort, patients with the advanced disease still fare poorly. Increasing evidence has shown the advantage of immunotherapy (PD-1/PD-L1 blockade) in relapsed/ refractory ENKTCL [7], and we guess the first-line use of immunotherapy in combination with asparaginasebased chemotherapy might further improve the prognosis of patients with advanced disease [8]. Recently, a novel molecular subtyping system was defined for ENKTCL, including TSIM, MB, and HEA subtypes, with both prognostic value and treatment guidance [9]. In the future, prospective clinical trials should be conducted incorporating the new risk models and molecular subtyping system, to further implement precision medicine in ENKTCL.

    Declarations

    Conflict of interest

    The author declares no conflict of interest.

    References

    1. Wang L, Li L R, Zhang L, et al. The landscape of new drugs in extranodal NK/T-cell lymphoma. Cancer Treatment Reviews, 2020, 89.

    2. Wang L, Wang Z, Chen X, et al. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved‐field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer, 2013, 119(2): 348-355.

    3. Wei L, Wang J, Ye J, et al. Long-term outcomes of patients treated with an EPOCHL regimen as first-line chemotherapy for newly diagnosed extranodal natural killer/ T-cell lymphoma: a retrospective single-center study. Leukemia & Lymphoma, 2020, 61(2): 337-343.

    4. Fox C P, Civallero M, Ko Y H, et al. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. The Lancet Haematology, 2020.

    5. Chen S Y, Yang Y, Qi S N, et al. Validation of nomogramrevised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. Leukemia, 2020: 1-13.

    6. Wang H, Wang L, Li C, et al. Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II Study. The Oncologist, 2020, 25(11): e1725.

    7. Wang L, Wang J. PD-1 blockade in extranodal NK/T-cell lymphoma: who is in charge?. Leukemia, 2020: 1-2.

    8. Wang L, Wang J. Extranodal natural-killer T-cell lymphoma: experience from China. The Lancet Haematology, 2020, 7(6): e441.

    9. Xiong J, Cui B W, Wang N, et al. Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma. Cancer Cell, 2020, 37(3): 403-419. e6.




    Subscribe to receive issue release notifications
    and newsletters from journals